NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models
International Journal of Toxicology · 2023
DOI: 10.1177/10915818231176971 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Toxicology, 2023. Verfasst von William Jordan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Greenfield Pathology Services, Inc, Greenfield, IN, USA. Hauptthemen laut MEDLINE: Ketamine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: NRx Pharmceuticals.
Abstract (Originalsprache)
Agents that act at the N-methyl-D-aspartate receptor (NMDAR), such as ketamine, have gained increasing attention as rapid-acting antidepressants; however, their use has been limited by potential neurotoxicity. Recent FDA guidance requires a demonstration of safety on histologic parameters prior to the initiation of human studies. D-cycloserine (DCS) is a partial NMDA agonist that, along with lurasidone, is being investigated as a treatment for depression. The current study was designed to investigate the neurologic safety profile of DCS. To this end, female Sprague Dawley rats (n = 106) were randomly divided into 8 study groups. Ketamine was administered via tail vein infusion. DCS and lurasidone were administered via oral gavage in escalating doses to a maximum of 2000 mg/kg DCS. To ascertain toxicity, dose escalation with 3 different doses of D-cycloserine/lurasidone was given in combination with ketamine. MK-801, a known neurotoxic NMDA antagonist, was administered as a positive control. Brain tissue was sectioned and stained with H&E, silver, and Fluoro-Jade B stains. No fatalities were observed in any group. No microscopic abnormalities were found in the brain of animal subjects given ketamine, ketamine followed by DCS/lurasidone, or DCS/lurasidone alone. Neuronal necrosis, as expected, was seen in the MK-801 (positive control) group. We conclude that NRX-101, a fixed-dose combination of DCS/lurasidone, when administered with or without prior infusion of IV ketamine was tolerated and did not induce neurotoxicity, even at supratherapeutic doses of DCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Greenfield Pathology Services, Inc, Greenfield, IN, USA.
- NRx Pharma, Wilmington, DE, USA.
ORCID-Profile: Michael T Sapko, Jonathan Javitt
Förderung
- NRx Pharmceuticals
Zitieren
APA
Jordan, W., Sapko, M. T., Siegel, R., & Javitt, J. (2023). NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models. International Journal of Toxicology. https://doi.org/10.1177/10915818231176971
Vancouver
Jordan W, Sapko MT, Siegel R, Javitt J. NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models. International Journal of Toxicology. 2023. doi:10.1177/10915818231176971
BibTeX
@article{Jordan2023,
author = {Jordan, William and Sapko, Michael T and Siegel, Richard and Javitt, Jonathan},
title = {NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models},
journal = {International Journal of Toxicology},
year = {2023},
doi = {10.1177/10915818231176971}
}
EUVIMED